Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Pavel G. Komarov"'
Autor:
Michelle Haber, Andrei V. Gudkov, Murray D. Norris, Glenn M. Marshall, Alan C. Sartorelli, Katerina V. Gurova, Pavel G. Komarov, Nadezhda Isachenko, Andrei Purmal, Janice Smith, Claudia Flemming, Chengyuan Xue, Anatoly Prokvolit, Marina Pajic, Jayne Murray, Fujiko Watt, Catherine A. Burkhart
Supplementary Table 1, Supplementary Figures 1-5 from Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac22996ef79fe9d1361b986939ba03a8
https://doi.org/10.1158/0008-5472.22378460.v1
https://doi.org/10.1158/0008-5472.22378460.v1
Autor:
Peter Krasnov, Ilia Toshkov, Michelle Haber, Michelle J. Henderson, Mahima Gupta, Pavel G. Komarov, Slavoljub Vujcic, Richard B. Lock, Yuan Tian, Murray D. Norris, Shiloh Middlemiss, Sangeeta Joshi, Denis N. Kazyulkin, Jean Veith, Lioubov G. Korotchkina, Eugene Kononov, Mikhail V. Chernov, Olga B. Chernova, Marina P. Antoch, Klaartje Somers, Andrei V. Gudkov, Alex Polinsky, Ekaterina L. Andrianova
Publikováno v:
Leukemia
Effective treatment of some types of cancer can be achieved by modulating cell lineage-specific rather than tumor-specific targets. We conducted a systematic search for novel agents selectively toxic to cells of hematopoietic origin. Chemical library
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::968c0d33d195d064d123c2e55b563e6b
https://pubmed.ncbi.nlm.nih.gov/31896781
https://pubmed.ncbi.nlm.nih.gov/31896781
Autor:
Liliya R. Novototskaya, Jelena O. Shneyder, Andrei V. Gudkov, Katerina I. Leonova, Marina P. Antoch, Pavel G. Komarov, Illia A. Toshkov, Elena A. Komarova
Publikováno v:
Cell Cycle. 9:1434-1443
It has been shown that genetic inhibition of p53 leads to enhanced proliferation of hematopoietic stem cells (HSCs). This could, in theory, contribute to the increased frequency of tumor development observed in p53-deficient mice and humans. In our p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91226b36c2c3fadd5eeba154cd1f8f0
https://doi.org/10.4161/cc.9.7.11508
https://doi.org/10.4161/cc.9.7.11508
Autor:
Janice Smith, Michelle Haber, Nadezhda Isachenko, Andrei Purmal, Anatoly Prokvolit, Catherine Burkhart, Marina Pajic, Chengyuan Xue, Murray D. Norris, Pavel G. Komarov, Andrei V. Gudkov, Claudia Flemming, Katerina Gurova, Jayne Murray, Alan C. Sartorelli, Glenn M. Marshall, Fujiko Watt
Publikováno v:
Cancer Research. 69:6573-6580
The multidrug resistance–associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma tumors resulted in increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c8e803432416a706ededc669048005d
https://doi.org/10.1158/0008-5472.can-09-1075
https://doi.org/10.1158/0008-5472.can-09-1075
Autor:
Pavel G. Komarov, Ivanda Pavlovska, Swati Sathe, Elena A. Komarova, Lyudmila G. Burdelya, Evguenia Strom, Olga B. Chernova, Roger M. Macklis, Rami Skaliter, Inna Shyshynova, Dmitry A. Bosykh, Andrei V. Gudkov
Publikováno v:
Nature Chemical Biology. 2:474-479
p53-dependent apoptosis contributes to the side effects of cancer treatment, and genetic or pharmacological inhibition of p53 function can increase normal tissue resistance to genotoxic stress. It has recently been shown that p53 can induce apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd368faf7f8117ea2497a0e0e714e1d9
https://doi.org/10.1038/nchembio809
https://doi.org/10.1038/nchembio809
Autor:
Kaihua Wang, Andrei V. Gudkov, Elena A. Komarova, Mikhail V. Chernov, Pavel G. Komarov, Nickolay Neznanov
Publikováno v:
Journal of Biological Chemistry. 278:15465-15468
Pifithrin alpha (PFTalpha) is a chemical compound isolated for its ability to suppress p53-mediated transactivation. It can protect cells from p53-mediated apoptosis induced by various stimuli and reduce sensitivity of mice to gamma radiation. Identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aacf36b45be95c3ced367ff1cf4468b3
https://doi.org/10.1074/jbc.c300011200
https://doi.org/10.1074/jbc.c300011200
Autor:
Pavel G. Komarov, Kaihua Wang, Tatiana V. Golovkina, Nickolay Neznanov, Dmitry V. Kuprash, Vadim I. Krivokrysenko, Andrei V. Gudkov, Elena A. Komarova, Mikhail V. Chernov, Sergei A. Nedospasov, Stanley L. Hazen, Elena Feinstein, Oskar W. Rokhlin, Marie Luise Brennan
Publikováno v:
The FASEB Journal. 19:1030-1032
Chronic inflammation is known to promote cancer, suggesting that negative regulation of inflammation is likely to be tumor suppressive. We found that p53 is a general inhibitor of inflammation that acts as an antagonist of nuclear factor kappaB (NFka
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6625fcd91fc1967af7db9d59ec81198
https://doi.org/10.1096/fj.04-3213fje
https://doi.org/10.1096/fj.04-3213fje
Autor:
Ahmad R. Safa, R. Martin Emanuele, Pavel G. Komarov, Lela Buckingham, Mannarsamy Balasubramanian, John S. Coon, Himanshu Shah
Publikováno v:
International Journal of Cancer. 65:74-79
Fatty acid ester surfactants, e.g., Cremophor EL and Solutol HS 15, that modulate multi-drug resistance (MDR) have been described; however, the drug potential of these preparations is unclear because of the molecular heterogeneity of these and other
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0750e2a1637831a6a94a208f3817ea3e
https://doi.org/10.1002/(sici)1097-0215(19960103)65:1<74::aid-ijc13>3.0.co
https://doi.org/10.1002/(sici)1097-0215(19960103)65:1<74::aid-ijc13>3.0.co
Autor:
Petro Ryabokon, Anatoly Prokvolit, Natalya V. Narizhneva, Katerina Gurova, Pavel G. Komarov, Andrei V. Gudkov, Andrei Purmal, Inna Shyshynova, Natalia D. Tararova
Publikováno v:
Cell cycle (Georgetown, Tex.). 8(24)
In prostate cancer (PCa) patients, initial responsiveness to androgen deprivation therapy is frequently followed by relapse due to development of treatment-resistant androgen-independent PCa. This is typically associated with acquisition of mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca0495b8468a5575b9852f68d68174f
https://pubmed.ncbi.nlm.nih.gov/20130446
https://pubmed.ncbi.nlm.nih.gov/20130446
Autor:
D. V. Kochetkov, Evguenia Strom, Julia E. Kravchenko, Andrei V. Gudkov, Elena I. Frolova, Elena Feinstein, P. M. Chumakov, I. Kovriga, Pavel G. Komarov, G. V. Ilyinskaya, L. S. Agapova
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 105(17)
Identification of unique features of cancer cells is important for defining specific and efficient therapeutic targets. Mutant p53 is present in nearly half of all cancer cases, forming a promising target for pharmacological reactivation. In addition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d4cc2bdb612d1eecdf1cceb06f5667
https://pubmed.ncbi.nlm.nih.gov/18424558
https://pubmed.ncbi.nlm.nih.gov/18424558